Tyler Van Guren's questions to Arvinas Inc (ARVN) leadership • Q2 2025
Question
Ikenna C. O, on for Tyler Van Guren, asked if Pfizer has indicated a willingness to revise the Vepdeq collaboration or return the rights, why they would return it after significant investment, and if a return would require a cash outlay from Arvinas.
Answer
CEO John Houston reiterated that the current 50/50 deal is less attractive for Pfizer now that development is focused only on second-line monotherapy. He confirmed Pfizer has shown no interest in funding further development. He stated clearly that if the asset is returned to Arvinas, the company will not spend its own money on further development but will instead run a process to find a new partner, thus avoiding a significant cash outlay.